Gene Gives a Boost to Tumor Suppression

Aug 18, 2006

Angiogenesis, or the growth of new blood vessels, is an important naturally occurring process in the body. As with normal tissues, tumors rely on angiogenesis to supply them with the oxygen and nutrients they need for growth.

This understanding has led researchers to explore antiangiogenic therapies for the suppression of tumor growth. Among the most potent known inhibitors of tumor angiogenesis are C-terminal fragments of collagen, one of the most abundant proteins in the body. However, it was unknown how production of antiangiogenic fragments from full-length collagen was controlled.

Now, researchers at the University of Massachusetts Medical School have demonstrated a connection between p53, a commonly known tumor suppressor, and the production of antiangiogenic collagen fragments.

Dubbed the “guardian of the genome,” p53 is the body’s primary tumor suppressing protein. Involved in regulating the response of cells to stress, p53 has the ability stop cells from dividing when they are damaged and, in some cases, to encourage such cells to destroy themselves via programmed cell death, or apoptosis. In the continuing efforts to understand how p53 influences cell death, scientists have found that the presence of p53 in tumors also influences angiogenesis.

In their paper, “p53-Mediated Inhibition of Angiogenesis through Upregulation of a Collagen Prolyl Hydroxylase,” published in the August 18 issue of Science, UMMS scientists, led by Howard Hughes Medical Institute Investigator Michael R. Green, MD, PhD, the Lambi and Sarah Adams Chair in Genetic Research and professor of molecular medicine and biochemistry & molecular pharmacology, sought to define the mechanisms by which p53 influences the regulation of angiogenesis. In doing so, Dr. Green and colleagues identified a gene—alpha II collagen prolyl hydroxylase [?(II)PH]—that is not only stimulated by p53 but is also necessary for the p53-mediated production of antiangiogenic collagen fragments. Remarkably, when ?IIPH was delivered to mice, tumor growth could be dramatically inhibited. These findings reveal both a genetic and biochemical linkage between the p53 tumor suppressor pathway and the production of antiangiogenic collagen fragments, as well as new strategies for combating cancer.

Source: University of Massachusetts Medical School, Worcester

Explore further: Four tobacco makers accused by French anti-smoking of collusion

add to favorites email to friend print save as pdf

Related Stories

Snapshot of cosmic burst of radio waves

11 hours ago

A strange phenomenon has been observed by astronomers right as it was happening - a 'fast radio burst'. The eruption is described as an extremely short, sharp flash of radio waves from an unknown source in ...

Journal team adds reviewer pay to open-access model

20 hours ago

A new open-access journal called Collabra plans to pay reviewers, and that's a twist in the world of scientific publishing. The reviewers get to exercise some options. They can keep the cash (generally a ...

Recommended for you

Ebola mistakes should serve a lesson says WHO

2 hours ago

The World Health Organization's chief admitted on Sunday that the UN agency had been caught napping on Ebola, saying it should serve as a lesson to avoid similar mistakes in future.

British Ebola nurse discharged from hospital

9 hours ago

A British nurse who contracted Ebola while working as a volunteer in Sierra Leone said she was "happy to be alive" as she was discharged from hospital on Saturday having made a full recovery.

Brazil finds coffee protein with morphine effect

9 hours ago

Brazilian scientists have discovered a protein in coffee that has effects similar to pain reliever morphine, researchers at the state University of Brasilia (UnB) and state-owned Brazilian Agricultural Research ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.